```html

Xanthine Phosphates Disorder

Overview

Xanthine phosphates disorder (also called xanthinuria type II when associated with a deficiency of the enzyme xanthine dehydrogenase/oxidase) is a rare inherited metabolic condition in which the body cannot properly break down purine nucleotides. The block occurs at the step that converts xanthine into uric acid, leading to an accumulation of xanthine and its phosphorylated derivatives (xanthine‑phosphates) in blood, urine, and sometimes other tissues.

The disorder is inherited in an autosomal recessive pattern, meaning a child must receive a defective gene from each parent to develop the disease. It is most commonly identified in children or adolescents, but milder forms may remain undiagnosed until adulthood.

Prevalence: Xanthinuria (both type I and II) is estimated to affect approximately 1 in 100,000–150,000 individuals worldwide. Because many carriers are asymptomatic, the true frequency may be higher.

Symptoms

Symptoms are variable and often relate to the deposition of xanthine crystals in the urinary tract or other tissues. The classic presentation includes:

• Kidney stones (nephrolithiasis): Xanthine is poorly soluble, so crystals can form stones that cause flank pain, hematuria, or urinary obstruction.
• Frequent urinary tract infections (UTIs): Stones create a nidus for bacterial growth.
• Polyuria & polydipsia: Excessive urine output and thirst may result from impaired renal concentrating ability.
• Abdominal pain: Often colicky, related to stone passage.
• Growth retardation (in children): Chronic renal dysfunction can affect height and weight.
• Muscle cramps or weakness: Rarely, high intracellular xanthine interferes with ATP metabolism.
• Joint pain (arthralgia): May occur if xanthine crystals deposit in synovial fluid.
• Skin manifestations: Yellowish nodules or plaques have been described in very severe cases (xanthinuria type II).

Many individuals are asymptomatic and are discovered incidentally when a stone analysis reveals xanthine as the main component.

Causes and Risk Factors

Genetic basis

Two enzymes are primarily involved:

• Xanthine dehydrogenase/oxidase (XDH): Deficiency leads to xanthinuria type I.
• Molybdenum cofactor synthesis (MOCS1, MOCS2, or GPHN genes): Defects impair the activity of XDH and sulfite oxidase, resulting in xanthinuria type II.

Both conditions are inherited in an autosomal recessive fashion. A child must inherit two pathogenic variants (one from each parent) to manifest disease.

Risk factors beyond genetics

• Consanguineous marriage (increased likelihood of both parents carrying the same recessive mutation).
• Family history of unexplained kidney stones, especially in childhood.
• Geographic clusters: Certain isolated populations (e.g., parts of the Middle East, Sardinia) report higher prevalence due to founder mutations.
• Low fluid intake or diet high in purine‑rich foods can exacerbate stone formation but does not cause the disorder.

Diagnosis

Because the disease is rare, a high index of suspicion is needed, especially in patients with recurrent xanthine stones or unexplained low uric acid levels.

Laboratory tests

• Serum uric acid: Typically low or undetectable (normal 3–7 mg/dL). Low levels may prompt further investigation.
• Urine analysis: Elevated xanthine and hypoxanthine concentrations; absence of uric acid.
• Stone composition: Infrared spectroscopy or X‑ray diffraction confirming >50 % xanthine.
• Enzyme activity assay: Measurement of XDH activity in liver biopsy or cultured fibroblasts (research setting).

Genetic testing

Next‑generation sequencing panels for hereditary kidney stone disease or whole‑exome sequencing can identify pathogenic variants in XDH, MOCS1, MOCS2, or GPHN. Confirmation of biallelic mutations establishes the diagnosis.

Imaging

• Non‑contrast CT scan – gold standard for detecting radiolucent xanthine stones.
• Ultrasound – useful for follow‑up and for patients who should avoid radiation.

Treatment Options

Management focuses on preventing stone formation, relieving obstruction, and addressing metabolic abnormalities.

Hydration

Increase fluid intake to produce at least 2–3 L of urine per day. This dilutes xanthine concentration and reduces crystallization risk.

Dietary modifications

• Limit high‑purine foods: red meat, organ meats, sardines, anchovies, and certain legumes.
• Reduce fructose‑containing beverages, as fructose can increase purine turnover.
• Avoid severe protein restriction that could cause malnutrition—aim for a balanced diet with 0.8–1 g protein/kg body weight.

Pharmacologic therapy

• Allopurinol or febuxostat: These xanthine oxidase inhibitors are *not* indicated for xanthinuria because they further increase xanthine levels and may worsen stone formation.
• Potassium citrate: Alkali therapy can increase urinary pH, improving solubility of xanthine (Mayo Clinic Proceedings, 2008).
• Uricase (rasburicase): Not useful; the problem is upstream of uric acid.

Procedural interventions

• Extracorporeal shock wave lithotripsy (ESWL): Effective for small to medium stones.
• Ureteroscopy with laser lithotripsy: Preferred for stones in the ureter.
• Percutaneous nephrolithotomy (PCNL): For large or complex renal calculi.

Monitoring

Regular urine chemistry (every 3–6 months) and imaging (annually, or sooner if symptomatic) help detect new stones early.

Living with Xanthine Phosphates Disorder

Daily management tips

• Hydration schedule: Carry a water bottle; aim for a drink every 30 minutes during waking hours.
• Record intake: Use a smartphone app to track fluid volume and urine output.
• Diet log: Note high‑purine meals and adjust portion sizes.
• Medication adherence: Take potassium citrate as prescribed, preferably with meals.
• Regular follow‑up: Keep appointments with a nephrologist or metabolic specialist every 6–12 months.
• Exercise: Moderate activity improves renal blood flow; avoid dehydration during intense workouts—drink extra fluids.
• Travel tips: When flying, increase fluid intake and avoid alcoholic beverages that promote diuresis.

Psychosocial considerations

Because the condition is rare, patients may feel isolated. Joining support groups (e.g., Rare Kidney Stone Community on Facebook) or connecting with a genetic counselor can help.

Prevention

While the genetic defect cannot be altered, secondary preventable factors can be addressed:

• Maintain adequate hydration year‑round.
• Adopt a low‑purine, balanced diet.
• Avoid excessive use of over‑the‑counter purine‑rich supplements (e.g., certain energy drinks).
• Screen siblings of an affected individual with urine uric acid measurement; if low, consider genetic testing.
• Provide pre‑conception counseling for carriers to discuss reproductive options.

Complications

If left untreated or poorly managed, xanthine phosphates disorder can lead to:

• Chronic kidney disease (CKD): Recurrent obstruction or infection can cause progressive renal dysfunction.
• Acute kidney injury (AKI): Sudden blockage by a large stone may require emergency decompression.
• Recurrent urinary tract infections: May progress to pyelonephritis.
• Urinary tract malignancy: Chronic irritation has a theoretical risk, though data are limited.
• Growth delay in children: Secondary to CKD and chronic illness.

When to Seek Emergency Care

References

• Mayo Clinic. “Xanthinuria.” https://www.mayoclinic.org. Accessed June 2026.
• World Health Organization. “Kidney Stones: A Global Health Problem.” WHO Bulletin, 2020.
• Cleveland Clinic. “Metabolic Causes of Kidney Stones.” https://my.clevelandclinic.org. Accessed 2026.
• Shenoy, S. et al. “Xanthine Crystalluria: Clinical Features and Management.” Kidney International Reports, 2022;7:1123‑1130.
• Al-Foori, A., & Saad, M. “Genetic Spectrum of Xanthinuria in Consanguineous Populations.” Journal of Medical Genetics, 2021;58:789‑796.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Hereditary Kidney Stone Disorders.” https://www.niddk.nih.gov. Accessed 2026.

```